DR. AMI P. VAIDYA MD
Prescription History 1982678413
Obstetrics & Gynecology - Gynecologic Oncology in Hackensack, NJ
Quality Rating: 83.48 out of 100 score
NPI Status: Active since February 13, 2006
Contact Information
92 2ND ST
HACKENSACK, NJ
ZIP 07601
Phone: (551) 996-5374
Fax: (551) 996-0572
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. AMI P. VAIDYA MD, an active Gynecologic Oncology specialist practicing in Hackensack, NJ. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 54 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydromorphone Hcl, which accounts for 39 claims alone.
Enoxaparin Sodium
Generic Formulation: Enoxaparin SodiumSpecialty: Gynecological OncologyProvider Avg Cost Per Claim
$95.38
State Avg Cost Per Claim
$113.93
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
Enoxaparin is used to prevent and treat harmful blood clots. This helps to reduce the risk of a stroke or heart attack. This medication helps keep your blood flowing smoothly by lowering the activity of clotting proteins in the blood. Enoxaparin is an anticoagulant, also known as a blood thinner. It is a type of heparin. Conditions which increase your risk of developing blood clots include certain types of surgeries (such as knee/hip replacement, abdominal), long periods of being immobile, certain types of heart attack, and a specific type of chest pain called unstable angina. For some medical conditions, enoxaparin may be used in combination with other blood thinners.
Hydromorphone Hcl
Generic Formulation: Hydromorphone HclSpecialty: Gynecological OncologyProvider Avg Cost Per Claim
$2.25
State Avg Cost Per Claim
$315.15
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.
This medication is used to help relieve moderate to severe pain. Hydromorphone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. AMI P. VAIDYA MD provides transparency into local medical care patterns within Hackensack, NJ.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Gynecologic Oncology** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
